IXHL - Incannex submits IND to begin testing of cannabinoid sleep apnea drug

2023-07-21 10:34:46 ET

Australian biotech Incannex ( NASDAQ: IXHL ) has submitted an investigational new drug application to the US Food and Drug Administration to begin clinical testing of its cannabinoid-based drug candidate IHL-42X for the treatment of obstructive sleep apnea.

The product is based on acetazolamide and dronabinol, a synthetic form of tetrahydrocannabinol, or THC.

Incannex believes the product would be an improvement upon the current standard of care for the condition, which is using a Continuous Positive Airway Pressure, or CPAP, machine.

More on Incannex:

Incannex Healthcare to redomicile from Australia to US, list on Nasdaq

For further details see: